Accuray Announces New CEO and Transformation Plan Amid Financial Challenges

Accuray, a prominent radiotherapy systems manufacturer, has unveiled a significant leadership change and strategic transformation plan aimed at improving its financial performance and market competitiveness. This move comes as the company faces ongoing challenges in the medical technology sector.

Leadership Transition and Strategic Initiatives

Steve La Neve, a veteran of the medical technology industry with over 40 years of experience, has been appointed as Accuray's new CEO, effective immediately. La Neve succeeds Suzanne Winter, who will retire after six years with the company but remain in an advisory role through November.

The leadership change is part of a broader transformation effort designed to expand margins, enhance competitiveness, and drive sustainable, profitable growth. Steven Mayer, who joined Accuray's board in June, has been named transformation board sponsor to work alongside La Neve and the management team in implementing these initiatives.

Financial Performance and Market Challenges

Accuray's transformation plan comes in the wake of financial challenges. The company released preliminary fiscal first-quarter 2026 results, reporting an adjusted loss before interest, tax, depreciation, and amortization of approximately $4 million, with revenue ranging between $92.5 million to $94 million.

This follows a challenging fiscal year 2025, during which Accuray reported a net loss of $1.6 million, an improvement from the $15.5 million loss in the previous year. While revenue increased by 3% year-over-year to $458.5 million, the company has faced headwinds, including slower order demand in the U.S. as hospitals delayed capital equipment replacements.

Industry Experience and Future Outlook

La Neve brings a wealth of experience to his new role at Accuray. His previous positions include serving as president of Globus Medical's trauma and joint reconstruction business unit, CEO of Bone Biologics, global president of Becton Dickinson's preanalytical systems, and global sector president for Medtronic's spine and biologics division.

The appointment of La Neve and the implementation of the transformation plan signal Accuray's commitment to addressing its financial challenges and improving its market position in the competitive radiotherapy systems sector. As the company moves forward with these initiatives, industry observers will be closely monitoring the impact on Accuray's performance and its ability to navigate the evolving landscape of medical technology.